Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-01-05
1996-09-17
Higel, Floyd D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
5142378, 5142382, 5142388, 5142392, 5142395, 514331, 514427, 514428, 514415, 514650, 514651, 544386, 544391, 544162, 544170, 546192, 546201, 546225, 548570, 548578, 560123, 560127, 560129, 562444, 562471, 564337, 564347, 564348, 564349, 564353, 564362, C07C 37055, C07C 3917, A61K 31205, A61K 31135
Patent
active
055568645
ABSTRACT:
Compounds of formula (I): ##STR1## [wherein: R.sup.1 is aryl; R.sup.2 is hydrogen, alkyl, alkoxy, halogen or cyano; R.sup.3 is a group of formula --B--NR.sup.4 R.sup.5, where R.sup.4 and R.sup.5 are independently hydrogen, alkyl or substituted alkyl or R.sup.4 and R.sup.5, together with the nitrogen to which they are attached, form a heterocycle, and B is alkylene or a group of formula --CH.sub.2 CH(OR.sup.6)CH.sub.2 --, where R.sup.6 is hydrogen, alkanoyl, substituted alkanoyl or arylcarbonyl, or a group of formula --D--R.sup.7, where D is a single bond or alkylene and R.sup.7 is a heterocycle; and A is alkylene; and pharmaceutically acceptable salts and esters thereof] are useful for the treatment and prevention of circulatory diseases and psychosis.
REFERENCES:
patent: 4485258 (1984-11-01), Kikumoto et al.
patent: 4792570 (1988-12-01), Nelson et al.
patent: 4853408 (1989-08-01), Clemence et al.
patent: 4892671 (1990-01-01), O'Neil et al.
Chemical Abstracts, vol. 116, No. 1, 6 Jan. 1992, Columbus, Ohio, Hara et al., "Antithrombotic effect of MCI-9042, a new antiplatelet agent on experimental thrombosis models". Abstract No. 454q.
Journal of Medicinal Chemistry, vol. 33, No. 4, 1990, Washington, US, pp. 1818-1823, Kikumoto et al., III, "Syntheses and platelet aggregation inhibitory and antithrombotic properties of [2-(.omega.-Aminoalkoxy)phenyl]ethyl benzenes".
Journal of Medicinal Chemistry, vol. 33, No. 4, 1990, Washington US, pp. 1194-1200, Huang et al. II, "Development of a novel series of (2-quinolinylmthoxy)phenyl-containing compounds as high-affinity leukotriene D4 receptor antagonists. 2. Effects of an additional phenyl ring on receptor affinity".
Journal of Medicinal Chemistry, vol. 35, No. 1, 1992, Washington US, pp. 189-194, Y. Watanabe et al, "Synthesis and 5-HT2 Antagonist Activity of Bicyclic 1,2,4-Trizol-3(2H)-one and 1,3,5-Triazine-2,4(3H)-dione Derivatives".
Asai Fumitoshi
Fujimoto Koichi
Ito Tomiyoshi
Koike Hiroyuki
Tanaka Naoki
Higel Floyd D.
Sankyo Company Limited
LandOfFree
.alpha.-.omega.-diarylalkane compounds serotonin-2 receptor agon does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with .alpha.-.omega.-diarylalkane compounds serotonin-2 receptor agon, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and .alpha.-.omega.-diarylalkane compounds serotonin-2 receptor agon will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-413371